Table 2 Transplant characteristics – total and according to donor type (MSD vs non-MSD) and across analysed era (2000–2007 vs 2008–2022).

From: Outcomes of allogeneic haematopoietic cell transplantation for myelofibrosis in children and adolescents: the retrospective study of the EBMT Paediatric Diseases WP

Variable

Modality

N

MSD

Non-MSD

Test p-value

[2000–2007]

[2008–2022]

Test p-value

Total

 

35 (%)

17 (48.6%)

18 (51.4%)

 

16 (45.7%)

19 (54.3%)

 

Donor type

Identical sibling

17 (48.6)

17 (100)

 

Not done

8 (50)

9 (47.4)

Not done

Matched other relative

3 (8.6)

 

3 (16.7)

 

2 (12.5)

1 (5.3)

 

UD 10/10

3 (8.6)

 

3 (16.7)

 

2 (12.5)

1 (5.3)

 

UD 9/10

2 (5.7)

 

2 (11.1)

 

0 (0)

2 (10.5)

 

UD (HLA not reported)

2 (5.7)

 

2 (11.1)

 

2 (12.5)

0 (0)

 

UCB 5/6

4 (11.4)

 

4 (22.2)

 

1 (6.2)

3 (15.8)

 

Double UCB (2/6; 3/6)

1 (2.9)

 

1 (5.6)

 

1 (6.2)

0 (0)

 

CB haploidentical

1 (2.9)

 

1 (5.6)

 

0 (0)

1 (5.3)

 

Haploidentical

2 (5.7)

 

2 (11.1)

 

0 (0)

2 (10.5)

 

Female donor to male recipient

No

27 (77.1)

14 (82.4)

13 (72.7)

0.69 f

12 (75)

15 (78.9)

1 f

Yes

8 (22.9)

3 (17.6)

5 (27.8)

 

4 (25)

4 (21.1)

 

Source of cells

BM

15 (42.9)

11 (64.7)

4 (22.2)

0.006 f

5 (31.2)

10 (52.6)

0.22 f

PB

14 (40.0)

6 (35.3)

8 (44.4)

 

9 (56.2)

5 (26.3)

 

CB & double CB

6 (17.1)

0 (0)

6 (33.3)

 

2 (12.5)

4 (21.1)

 

Conditioning regimen

Bu+Cy

16 (45.7)

11 (64.7)

5 (27.8)

Not done

10 (62.5)

6 (31.6)

Not done

Bu+Cy+Flu

1 (2.9)

0 (0)

1 (5.6)

 

1 (6.2)

0 (0)

 

Bu+Cy+Flu+Arac

1 (2.9)

1 (5.9)

0 (0)

 

0 (0)

1 (5.3)

 

Bu+Cy+Mel

3 (8.6)

1 (5.9)

2 (11.1)

 

2 (12.5)

1 (5.3)

 

Bu+Flu

2 (5.7)

1 (5.9)

1 (5.6)

 

0 (0)

2 (10.5)

 

Bu+Flu+Thio

1 (2.9)

1 (5.9)

0 (0)

 

0 (0)

1 (5.3)

 

TBI+Bu+Cy+Flu

1 (2.9)

0 (0)

1 (5.6)

 

0 (0)

1 (5.3)

 

TBI alone

1 (2.9)

0 (0)

1 (5.6)

 

1 (6.2)

0 (0)

 

Treo+Flu+Thio

4 (11.4)

0 (0)

4 (22.2)

 

0 (0)

4 (21.1)

 

Treo+Flu

1 (2.9)

0 (0)

1 (5.6)

 

0 (0)

1 (5.3)

 

Treo+Cy+Mel

1 (2.9)

0 (0)

1 (5.6)

 

0 (0)

1 (5.3)

 

Cy+Flu

1 (2.9)

1 (5.9)

0 (0)

 

0 (0)

1 (5.3)

 

Flu+Mel

2 (5.7)

1 (5.9)

1 (5.6)

 

2 (12.5)

0 (0)

 

Myeloablative regimen

No (CyFlu and FluMel)

3 (8.8)

2 (11.8)

1 (5.9)

1 f

2 (13.3)

1 (5.3)

0.57 f

Yes

31 (91.2)

15 (88.2)

16 (94.1)

 

13 (86.7)

18 (94.7)

 

missing

1

0

1

 

1

0

 

GVHD prophylaxis

CSA + MTX

19 (57.6)

13 (81.2)

6 (35.3)

Not done

11 (78.6)

8 (42.1)

Not done

CSA

6 (18.2)

0 (0)

6 (35.3)

 

2 (14.3)

4 (21.1)

 

CSA + MMF

3 (9.1)

1 (6.2)

2 (11.8)

 

0 (0)

3 (15.8)

 

CSA + MMF + TACRO

1 (3)

0 (0)

1 (5.9)

 

0 (0)

1 (5.3)

 

PT-CY + CSA

1 (3)

0 (0)

1 (5.9)

 

0 (0)

1 (5.3)

 

ATG only

2 (6.1)

1 (6.2)

1 (5.9)

 

1 (7.1)

1 (5.3)

 

MTX

1 (3)

1 (6.2)

0 (0)

 

0 (0)

1 (5.3)

 

missing

2

1

1

 

2

0

 

TCD in vivo

No

9 (27.3)

7 (43.8)

2 (11.8)

0,06 f

5 (35.7)

4 (21.1)

0,44 f

Yes

24 (71.7)

9 (56.2)

15 (88.2)

 

9 (64.3)

15 (78.9)

 

missing

2

1

1

 

2

0

 
  1. MSD matched sibling donor, non-MSD non-matched sibling donor, UD unrelated dor, CB cord blood, UCB unrelated cord blood, BM bone marrow, PB peripheral blood, Bu busulfan, Cy cyclophosphamide, Flu fludarabine, Thio thiothepa, Mel melphalan, Treo treosulfan, TBI total body irradiation, ATG anti-thymocyte globuline, CSA cyclosporine A, MFF mycophenolate mofetil, TACRO, tacrolimus, MTX methotrexate, PT post-transplantation, TCD T-cell depletion.
Back to article page